

Treating Radiation Proctitis (RP)

PuraStat™ Advantages

PuraStat's core technology is derived from self-assembling peptides (SAPs). The discovery of SAP technology by an Massachusetts Institute of Technology (MIT) post-doctoral researcher led to a completely new field of peptide biotechnology. Research found that this new technology could be used in areas including tissue engineering, 3D tissue cell culture, and surgical and clinical applications.



Highly suitable for RP

A safe, effective and non-toxic modality, which reduces the need for thermal techniques



Synthetic peptide technology

An inert hydrogel that contains no animal/plant derivatives and mimics the human extra-cellular matrix (ECM)



Easy to use and apply

Allows multiple quick and easy applications to achieve better outcomes, even in high-risk patients

Patient Impact

Scan the QR code below to hear directly from patient, Victor, sharing his reality of living with RP and his experience following treatment with PuraStat.




"It's just getting your life back, that's what it's basically about"

- Victor

<< Watch the full video

Also available on YouTube: <https://bit.ly/3LXCL8c>



PuraStat for RP: Clinical Evidence



Clinical Study:

Endoscopically delivered PuraStat for the treatment of severe haemorrhagic radiation proctopathy: A service evaluation of a new endoscopic treatment for a challenging condition

Henson C., and White K., 2021



Clinician Video:

Personal experience sharing of using PuraStat for radiation proctopathy

Dr John Hancock, Consultant Gastroenterologist, North Tees and Hartlepool NHS Foundation Trust



Case Report:

Haemostatic properties of PuraStat in radiation proctopathy

Dr Sergio Coda, Consultant Gastroenterologist and Clinical Director of Bowel Screening Programme, Queen's Hospital, Barking, Havering and Redbridge University



From a patients' perspective, **patients are very reassured** since I've started using PuraStat. They've communicated their improvements to me, [...] particularly regarding the **reduction in weekly bleeding episodes**.

We've also noticed an **improvement in haemoglobin levels**, resulting in less need and dependence on iron supplementations or transfusions.




*Dr Sergio Coda
Consultant Gastroenterologist and Clinical Director of Bowel Screening Programme, Queen's Hospital, Barking, Havering and Redbridge University, UK*


Application Tips for RP




Remove any excess blood/mucus from the site.




Position the catheter as close as possible to the bleeding site.



Push down on the syringe slowly to apply a thin layer of PuraStat.



Use a 'painting' or 'pipetting' technique* to fully cover the bleeding site.



Haemostasis is achieved. Usually 3 treatments are required, in 3-4 week intervals*.

For application within gastroenterology, PuraStat is indicated for¹:

- ▶ Achieving haemostasis in bleeding from small blood vessels and oozing from capillaries of the GI tract following surgical procedures and surrounding tissues [when haemostasis by ligation or standard means is insufficient or impractical]
- ▶ Reduction of delayed bleeding following gastrointestinal endoscopic submucosal dissection (ESD) procedures in the colon

Available in 1 ml (621-034), 3 ml (621-035) and 5 ml (621-036)

3-D Matrix Europe SAS
11 chemin des Petites Brosses
69300 Caluire-et-Cuire-FRANCE
Tel: +33 (0)4 27 19 03 40
infoeu@puramatrix.com

Distributed by:

*Based on feedback from healthcare professional users.

References:

(1) PuraStat IFU-007 Rev 2



Please visit for more information:
www.3dmatrix.com

PuraStat is a class III medical device, CE marked according to European council directive 93/42/EEC on medical devices and its relatives

